I have 50 reasons why IBIO has not been priced right at this PPS. And I have posted them to many times... I will post again on demand. Its cheap and the Market cap does not reflect their foot print in the industry, patents and backing.
advantages over other systems
Ability to synthesize complex proteins at which other systems have failed
Simplicity, scalability and flexibility
Reduced capital investment
Lower operating costs
Rapid production times – gene sequence to factory-scale protein harvest
Eliminates the need of bioreactors
Low risk of contamination by animal pathogens WHO, GE, CALIBER ,NOVICI,IBIO ,Fraunhofer USA Center for Molecular Biotechnology , GATES, DOD, DARPA, Kanematsu Chemicals Corporation ,Oswaldo Cruz Foundation-brazil, China building 3 IBIO plants all with out contracts the basher would like you to think.......its about many successes and diseases. ...... , ITS disruptive- iBioLaunch platform has been proven 48____ BOB SIMON tribute and last story for 60 minutes was on EBOLA and ZMAPP – This doubled IBIO stock asked SIMON ASKED –Will we be prepared for the next outbreak? Trials in FEB 2015, Liberia -ZMAPP next week. He talked of Kentucky bio, BARDA and emergency responses. We are looking for different ways to produce! YESSSssss- DDaaaa . They stated not easy to make and it takes a lot of tobacco and work….. So little of the drug WHY? Mapp has a work force of 9 !!! Only. This is why IBIO Doubled! IBIO has optimization and mass production techniques. He interviewed Kent Bradley. Whaley, Zeitlin and Gary Kobinger are with MAPP and working to mass produce it.
US health officials have asked three advanced biology laboratories to submit plans for producing the experimental Ebola drug ZMapp .. Biomedical Advanced Research and Development Authority (BARDA) are evaluating proposals …… BARDA will then select one or more of the labs to start producing ZMapp, which is currently manufactured in tobacco plants by Kentucky Bioprocessing, a unit of Reynolds American Inc. As IBIO investors we know Texas has teamed up with Caliber Biotherapeutics of Bryan, Texas, on tobacco plant-based manufacturing as part of the Government emergency team 49) being FIRST ! it's getting in on the right companies first. That means locating obscure biotech companies that most investors don't even know exist. Double digit to 100% happen as in IBIO after the 60 minute piece with Simon.
1) The Plant- PMP industry is not as internally competitive as investors make them out to be. During the doctors discussions with Robert Erwin the assertion was that iBio patents dominate in the US and ICON dominates in Europe which are the respective locations for the company’s headquarters. 2. Investors need to realize that long term success is not made of winning any single contract. They have focused on building an infrastructure at a relatively low cost in comparison to other small biotech companies. 3) Transgenic expression (ICON)(MAPP,zmapp) VS. Transient gene expression (IBIO patented) is, among the industry, seen as the way to go and has made major advancements in the last decade that makes transgenic expression in plants less feasible. Its in the patents and science. iBio patents in the US dominates MagnICON patents since they received their patents in the US first. 4) 4. iBio and Caliber Biotherapeutics do not currently have total exclusivity for all product development. Caliber Biotherapeutics
• Early developments and major players now funded with DARPA money for their creation but they are not technically a part of Texas A&M CIADM. These companies are independent but work together and will most likely follow their past and designed purpose. ********** 1.1 trillion spending bill. The measure retains cuts negotiated in previous budget battles and rolls back some banking regulations. But it also retains spending for Obama's health care law and pays for the administration's fight against Ebola. $5.4 Billion Ebola Funding breakdowns
See esp. $2.742 billion portion....
-- $112 million will be appropriated to DoD for Ebola response and preparedness. Of this, $45 million will go to the Defense Advanced Research Projects Agency’s long-range research programs; $50 million to nearer-term research programs of the Defense Threat Reduction Agency; and $17 million for procurement of equipment.
-- $25 million will be appropriated for Ebola response and preparedness at FDA, including “increased medical countermeasure activities.”
-- $2.742 billion will be appropriated to HHS to respond to the Ebola epidemic in the United States and other countries threatened by the virus. Funding will be used to:
(1) develop vaccines and treatments;
(2) train health care workers;
(3) bolster quarantine stations at ports of entry;
(4) create isolation units;
(5) reimburse hospitals providing care; and (5) send CDC personnel to countries affected by Ebola.
-- $238 million will be appropriated to the NIH for Ebola-related research.
-- $2.5 billion will be appropriated to DOS “to respond to the Ebola epidemic in West Africa and to strengthen public health capacity in other countries threatened by the virus.”
Right know they need a huge win like Ebola or a drug to go to market using plant antibodies, proteins or PMP (plant products). After the catalyst the PPS will go up 10 fold. I say it is worth 3 right now with out positive Ebola ZMAP testing . After and the discovery of PMP and not animal ZMAP we will double. With GSK,TEXAS A M , Caliber , NOVICI or CMB , cruz ties we will be at 5 dollars. The iBioLaunch technology platform addresses several multi-billion dollar markets. Its applicability to a broad range of product classes enables iBio to target global commercial collaborations in high-growth markets such as orphan biologics ($54.6 billion in 2009), biosimilars/bio-betters (~$80 billion worth of biologics sales will be susceptible to biosimilar competition, by 2013) and new proprietary biologics. The speed and superior economic scalability of the iBioLaunch™ technology make it the ideal platform for new personalized therapeutics as well as for vaccines ($32 billion in 2013).
There are an estimated 120 biologic on the market today and hundreds more in development. The global market for biopharmaceuticals is growing as more and more companies realize the advantages of biotech, and it is expected to reach 239 billion by 2015. The IBIO technology provides several advantages over other drug production methods such as mammalian cell culture or fermentation systems. The process speeds up development and is capable of reducing manufacturing costs by 90%..speed, cost, ramp, . They have the USA patents and research that is years ahead of the competition. .. The iBioLaunch platform offers significant advantages over earlier plant-based methods that rely on transgenic plants or plant cell cultures. These include the speed at which different proteins can be expressed and produced at commercial scale, which presents a significant commercial advantage, as well as public safety benefits when vaccines for pandemic diseases are required. Other advantages include scalability, no risks of contamination by animal pathogens, and the ability to express complex proteins at which other systems have failed......
There are currently five known strains or species of the virus. Ebola has mutated over 300 times so far with over 7000 deaths in many countries.
IBIO has products that reach at least a 24 billion $$$ market... iBio has a long history of successful collaboration with other organizations to develop innovative technology and products. Its partner of nearly ten years in the development of its patented iBioLaunch platform was the Fraunhofer USA Center for Molecular Biotechnology in Newark, Delaware. The success of iBio in combination with Fraunhofer has attracted over $60 million in funding from the U.S. government and the Bill & Melinda Gates Foundation for other rapid response and tropical disease priorities. This success also led to the creation of DARPA's Blue Angel program which funded the facilities at Caliber.
The iBioLaunch expression platform has been used to manufacture vaccine candidates that represent a broad range of viral, bacterial, and parasitic threats to human health. The technology has been used to successfully produce vaccine components that could not be manufactured using bacterial, yeast, or animal cell expression systems, demonstrating a breadth of application that is unmatched. Each of these vaccines is available to be licensed from iBio along with the iBioLaunch manufacturing platform, providing a turnkey entry into vaccine development and manufacturing.
Yellow Fever — Yellow fever was the first human disease to be proven to be caused by a virus, and it is transmitted by mosquito bite. A highly effective vaccine (17D) was developed in 1937 by Max Theiler, for which he was later awarded the Nobel Prize. This vaccine is a weakened but live version of the virus, and is produced in embryonated chicken eggs. However, like other vaccines produced in eggs, individuals allergic to eggs cannot receive the vaccine, and other individuals may have side effects, including neurologic effects, and organ failure. Children, the elderly, and immunocompromised individuals should not receive the 17D yellow fever vaccine, and the side-effect profile has been increasingly unacceptable in regions of the world where yellow fever is present, but acceptably managed. Because of these reasons, a next-generation yellow fever vaccine is of high importance in tropical nations, and a subunit vaccine made in plants is likely to have an improved safety profile while at the same time being highly effective in protection. In partnership with Fiocruz/Bio-Manguinhos of Brazil, iBio and its research collaborator, the Fraunhofer USA Center for Molecular Biotechnology, have undertaken the development of this next-generation yellow fever vaccine. A license agreement for the iBioLaunch manufacturing platform applied to the yellow fever vaccine has been established with Fiocruz/Bio-Manguinhos and, by mutual agreement, may be expanded to include other product applications.
Influenza vaccines — As part of its collaboration with external agencies such as the Bill & Melinda Gates Foundation Global Health Initiative and the US Department of Defense Advanced Research Projects Agency, subunit vaccines for avian influenza (H5N1) and pandemic influenza (H1N1) have been created and advanced into human safety and immunogencity clinical studies. These vaccines consist of the viral hemagglutinin (HA) antigen, which is known to produce a protective immune response in humans.
Malaria — Malaria is one of the greatest threats to human health in the world. A vaccine for malaria has been elusive, since the malaria parasite changes body forms during its life cycle, and is kept hidden from the human immune system for much of its life. The iBioLaunch-manufactured vaccine candidate is novel in that it is directed against a malaria parasite antigen. This is commonly displayed on the parasite forms present in the gut of transmitting mosquitos. Individuals immunized against this mosquito-borne form of the parasite share anti-malaria antibodies with the mosquito when the insect takes a blood meal, and these antibodies block the maturation of the parasites in the insect gut, ending the transmission cycle from mosquito to man and back to mosquito. This vaccine candidate, which has shown great promise in laboratory studies of malaria transmission, was developed in a partnership with the Bill & Melinda Gates Foundation Global Health initiative.
Hookworm — Hookworms are parasitic nematodes that cause anemia and child development issues and retardation in infected individuals, most commonly in tropical and subtropical environments. iBioLaunch technology is being used to produce a vaccine antigen to an enzyme found in the gut of the hookworm. Antibodies to this gut enzyme block its action, which is normally to break down hemoglobin in the blood as a source of iron for the hookworm. When this gut enzyme is blocked, the hookworm dies, allowing infected patients to resume a healthier life. The antigenic form of this hookworm gut enzyme has proven to be impossible to manufacture efficiently using bacterial, yeast, or animal cell expression systems. However, commercially useful amounts of the antigen can be manufactured using the iBioLaunch plant expression technology, and development of a vaccine in partnership with the Sabin Vaccine Research Institute is proceeding towards human safety and efficacy studies.
Human papilloma virus — Human papilloma virus has been shown to cause a number of human cancers, chiefly cervical cancer but also increasingly anogenital and oral cancers. There a multiple oncogenic serotypes of HPV, and extensive efforts have been made to produce effective vaccines to prevent HPV infection. However, iBioLaunch technology has been used to produce an experimental vaccine to one serotype of HPV (HPV-16) which causes the regression and loss of established HPV tumors in an animal model. Such a vaccine in humans has the potential to treat patients with established HPV-related cancers, for which current therapeutic options involve surgical resection followed by chemotherapy and/or radiation treatment.
Bacterial pathogens — The iBioLaunch system has been used to produce vaccines against plague (Yersinia pestis) and anthrax (Bacillus anthracis). The plague vaccine consists of two bacterial antigens (F1 and LcrV) and has been demonstrated in primates to provide complete protection against inhaled plague challenges when administered with an adjuvant.
A vaccine candidate to prevent anthrax infection has been manufactured, and comprises a portion of the pathogen’s Protective Antigen and Lethal Factor proteins. Mice immunized with this dual-antigen vaccine made antibodies to anthrax, which were successful in neutralizing bacterial infectivity in laboratory tests.
) Opportunities for vaccine and antibody products using the iBioLaunch™ platform. The efficiency and flexibility of iBioLaunch™ technology and the company's issued patent portfolio have attracted increasing commercial and scientific interest in light of serious challenges such as the Ebola virus disease outbreak in West Africa.
3) Opportunities for iBio's subsidiary operations and business relationships in Brazil. The iBioLaunch™-based recombinant yellow fever vaccine continues development with collaborators in Brazil. Management will discuss previously announced product candidates under review for potential development for the Brazilian market.
4. Opportunities in Japan. iBio has extended business development activities into Japan in collaboration with Kanematsu Chemicals Corporation, and will discuss the company's general approach to developing opportunities in non-U.S. markets.
5. Programs involving government and NGO sponsorship. Phase 1 clinical trials of a malaria transmission-blocking vaccine and a hookworm vaccine are underway, both of which are non-commercial products fully funded by third parties. These and potential new programs provide valuable data on medically important applications of iBio's proprietary technology.
Overview of iBio's development of IBIO-CFB03. iBio has collaborated with Dr. Feghali-Bostwick, the inventor of IBIO-CFB03, at the Medical University of South Carolina (MUSC) during 2014 to develop this drug candidate for clinical trials.
They have solutions in a huge 24 billion dollar market... BY product make-up- IBIO Target Markets
Based on scientific data produced by FhCMB, it believes that its platform technology is well-suited for application to both vaccines and therapeutic proteins.
• Vaccine Market. The company believes its opportunities to establish commercial collaborations in vaccine markets will arise in two categories: a) Companies interested in tradition vaccine products well established in clinical practice; and b) Governments around the world increasingly committed to achieving autonomy in manufacturing vaccines to protect their citizens from natural outbreaks or deliberate infection. It believe the company's platform, due to its product flexibility and projected advantages in cost and time of implementation over traditional processes, will be an attractive option for both commercial and government collaborators. The first disease category in which the company has focused on demonstrating the applicability of its technology for vaccines is influenza.
• Influenza Market. The company believes that it can achieve commercial success through establishing commercial collaborations for the use of the company's iBioLaunch platform technology in the development of vaccines for prevention of influenza infections and to the establishment of validated technology for rapid response to the outbreak of new strains of influenza. IBIO believes that market demand for influenza vaccines and therapeutics is growing quickly, driven by the pandemic threat of H1N1 swine-like influenza and the continuing threat of a potential pandemic outbreak of avian influenza. Vaccine sales in the seven major markets (US, UK, Germany, France, Italy, Spain and Japan) are expected to more than double to $5 billion by 2016. These estimates are based on a market analysis conducted by Datamonitor. Datamonitor also states that current manufacturing capacity, even prior to the H1N1 outbreak, is not sufficient to provide enough flu vaccine even for high-risk populations. Consequently, one of the most important challenges facing the industry is the development of novel, faster manufacturing methods that offer higher yields.
• The company believes that, with further clinical testing and development, the iBioLaunch platform, its proprietary technology platform described in the following paragraphs, will be able to address such a critical need. The company has demonstrated the efficiencies of this technology at a laboratory level by producing candidate influenza vaccines in weeks versus the months required for commercially-used chicken egg methods. The yields iBio Inc. have obtained in these laboratory experiments are high enough to be competitive with other methods if it can achieve the same yields and the same time efficiencies on a commercial scale. The company, however, has not yet tested iBio's technology at the scale that will be required for commercial use, nor at a scale sufficient to conclude what its commercial cost of goods will be.
• Biodefense Vaccine Market. In collaboration with FhCMB and future commercial partners, iBio Inc. expect to participate in the introduction of important new prevention and treatment products as potential countermeasures against bioterrorism threats and for use in the developing world. The company does not currently have any commercial partners.
• Markets for Therapeutic Proteins. IBio's technology is broadly applicable to the production of proteins ranging in size and complexity from monoclonal antibodies to smaller proteins such as interferons, growth factors, and enzymes. The potential market for application of its platform to therapeutic proteins is large and can be divided into two types of opportunities: a) Proteins for treatment of orphan diseases; and b) Proteins for bio-similar (bio-generic) products.
• Treatment of Orphan Diseases. The worldwide market for orphan disease therapy is over $80 billion and approximately half of that is addressed through biologic rather than chemical drugs. Well-known products in this category include human enzymes for treatment of lysosomal storage diseases and products for treatment of less-common types of cancer. The incentives for companies to invest in new treatments for smaller patient populations are substantial, both due to tax incentives and also due to the profit margins that are typically seen for these products. To date, the FDA has granted more than 2,000 orphan designations to products in various stages of development. IBIO expects to attract commercial interest in iBio's platform for manufacturing certain orphan biologic drugs from companies that have not yet committed to the more expensive traditional bioreactor alternatives.
• Bio-similar Products. The potential market for bio-similar products is large and growing according to industry analysts. Worldwide sales of the eight highest selling patent-protected products is approximately $26 billion, and as the patents on these and other products are expiring, interest in competing with generic or bio-similar versions of these well-established clinical products is growing. Due to the efficiency of its platform, it believe iBio Inc. will be able to establish commercial collaborations to participate in this growing market segment.
I am sure he is still looking in Hawaii and Africa... HE is about as clever as a mule is a horse race.
TRUMP is a Buffoon ............ He is Dicktator. He is worst then Biden when it comes to putting his foot in his mouth. HE is no politician. NOT that politicians are good but he is a complete DICKKT. COLORFUL , rich and on top of the business community yes, but a leader for the people HELLP NO! He would have us in a war faster then McCain. HIS arrogance would be enough in its self to isolate us from the world and set us back 20 years in world affairs. HAVE you not heard him say the world should respect and fear us that in its self would bring terrorist to our back door.
Half time report on CNBC said they all liked oil. This blew me away . JOE has been in it for a while and he is up good. Those Monster brothers JON and DOC are even talking like oil has an up move coming. JIM was very upbeat. I might add as I added with a couple other oil stocks.
Mid day a panel of traders on CNBC said they liked oil here. JOE said he has been in it for a while and doing well. These guys are usually pretty sharp, especially DOC.